Publication profile. Haihe Ruan's record comprises 9 indexed papers with an h-index of 7 and 443 total citations β a solid citation-per-paper average (~49) that indicates the work has been genuinely used by the chromatin/genome-structure community, though the modest h-index suggests either an early/mid-career stage or a heavily collaborative (non-lead) role on many outputs.
Scientific identity and coherence. The portfolio is unusually coherent: nearly all papers concern nucleosome-level chromatin biophysics. Two papers address how pathogenic repeat expansions (GAA.TTC in Friedreich's ataxia; ATTCT repeats in spinocerebellar ataxia type 10) form nucleosome-resistant structures, with repeat interruptions further enhancing nucleosome assembly barriers. A second thread covers chromatin regulation β H2A.Z-mediated nucleosome unwrapping and CTCF binding in mouse ES cells, local chromatin states predicting transcription potential during neural progenitor differentiation, and cell-cycle-dependent CENP-N recruitment to centromeric chromatin. This demonstrates methodological depth in chromatin biochemistry/structural analysis applied consistently to genome organization questions.
Strengths. The work sits at a mechanistically rigorous interface of chromatin structure and disease (trinucleotide repeat disorders), where nucleosome-assembly assays provide direct physical evidence rather than purely correlative genomics. The senescence work (E2F1-FoxO axis; oncogene-induced telomere dysfunction in cancer precursor lesions) adds translational breadth.
Blind spots and uncertainty. Affiliation data is missing, preventing verification of institution, career stage, or independence. Duplicate entries for the neural progenitor paper suggest data-quality noise. Citation counts per individual paper and author position are not provided, so we cannot distinguish first-author foundational work from shared authorship. OpenAlex verification failed (rate-limited), so metrics rest on a single source. Confidence in this assessment is moderate.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.